Background {#Sec1}
==========

Erythroderma is a severe and potentially life-threatening dermatitis described as an intense and widespread erythema typically involving greater than 90% of the body surface area, with a variable degree of exfoliative skin scaling (see Figs. [19.1](#Fig1){ref-type="fig"} and [19.2](#Fig2){ref-type="fig"}) \[[@CR1], [@CR2]\]. It is a manifestation of a wide range of cutaneous and systemic diseases including infection, malignancy, and drug hypersensitivity reactions \[[@CR3]\].Fig. 19.1Widespread erythema and areas of sparing in a patient with unclear etiology of erythroderma. [(]{.ul}Used with permission from Rothe et al. \[[@CR3]\])Fig. 19.2Diffuse erythema and scaling of a 14-year-old girl with erythroderma of unknown etiology. (Source (open access): <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2800861/>)

There are numerous systemic and cutaneous diseases known to be associated with erythroderma (Tables [19.1](#Tab1){ref-type="table"} and [19.3](#Tab3){ref-type="table"}). The most common trigger of erythroderma is an exacerbation of an underlying dermatitis, most commonly psoriasis (Fig. [19.3](#Fig3){ref-type="fig"}) (23%), atopic dermatitis, and contact dermatitis \[[@CR4]--[@CR7]\]. Drug reaction is another important cause of erythroderma, implicated in 20% of cases, with at least 135 drugs suspected as potential causative agents \[[@CR5]--[@CR8], [@CR10]\]. A common malignancy associated with erythroderma is cutaneous T-cell lymphoma ( CTCL) \[[@CR3], [@CR7], [@CR9]\]. Idiopathic erythroderma, where no cause can be elucidated despite thorough serial investigations, occurs in approximately 30% of cases. " Red man's syndrome" associated with rapid vancomycin infusion is considered to be an example of idiopathic erythroderma \[[@CR3]--[@CR5], [@CR8], [@CR10], [@CR11]\].Table 19.1Common causes of erythroderma (remembered by mnemonic IDSCALP) \[[@CR54]\]I*Idiopathic -- 30%Infections* (HIV, HSV, dermatophytosis, scabies)D*Drug allergy -- 20%*S*Seborrheic dermatitis -- 2%Sarcoidosis*C*Contact dermatitis -- 3%Connective tissue diseases*A*Atopic dermatitis -- 10%Autoimmune* (systemic lupus/dermatomyositis/bullous pemphigoid/pemphigus foliaceus/lichen planus/graft vs host disease)L*Lymphoma and leukemia -- 14%* (including Sezary syndrome)P*Psoriasis -- 23%* (including reactive arthritis/pityriasis rubra pilaris)Fig. 19.3Patient with erythrodermic psoriasis and classic plaques on elbows. (Used with permission from Rothe et al. \[[@CR3]\])

Because erythroderma is often associated with scaling and extensive erythema, it is often difficult to discern the typical features characteristic of the preexisting, underlying condition. For this reason, diagnosis and management strategies can be challenging \[[@CR1], [@CR2]\].

Erythroderma is thought to be mediated by a complicated process of inflammatory cell interactions, resulting in a dramatic turnover of epidermal cells \[[@CR12]\]. It is a rare condition, with an incidence rate of approximately 1 per 100,000 adults \[[@CR13]\]. Erythroderma is rare in children and occurs at an average age of 42--61 years \[[@CR14]\]. When age of onset is less than 40 years, the condition is typically a result of atopic dermatitis, seborrheic dermatitis, staphylococcal scalded skin syndrome, or a hereditary ichthyosis \[[@CR14], [@CR15]\]. It is more common in males and has no racial predilection \[[@CR3]--[@CR7], [@CR9], [@CR16]\].

Classic Clinical Presentation {#Sec2}
=============================

The typical presentation of erythroderma is characterized by erythematous patches which progressively increase in size and coalesce to cover most of the body's surface, with occasional islands of sparing \[[@CR17]\]. Scaling can occur as large sheets or small flakes and generally erupt 2--6 days after the onset of erythema. Pruritus is common and is most severe in patients with atopic dermatitis and Sezary syndrome (a leukemic variant of cutaneous T-cell lymphoma where atypical lymphocytes known as Sezary cells are found in peripheral blood; see Fig. [19.4](#Fig4){ref-type="fig"}) \[[@CR50]\]. The skin may feel leathery secondary to excessive scratching and there may be eyelid and periorbital involvement \[[@CR18]\].Fig. 19.4Patient with Sezary and skin fissuring. (Used with permission from Rothe et al. \[[@CR3]\])

Especially in chronic conditions, patches of hypopigmentation can be observed, and hair and nails may shed \[[@CR19]\]. Nails may also become ridged, thickened, and brittle \[[@CR9], [@CR17], [@CR20], [@CR21]\]. Individuals with long-standing erythroderma may present with cachexia, vitiligo, diffuse alopecia (see Fig. [19.5](#Fig5){ref-type="fig"}), and thickened palms and soles (Table [19.2](#Tab2){ref-type="table"}) \[[@CR18], [@CR22]\].Fig. 19.5Diffuse alopecia in a patient with chronic idiopathic erythroderma. (Used with permission from Rothe et al. \[[@CR3]\])Table 19.2Classic features of erythrodermaSkinWidespread erythemaVariable degree/character of scaling (2--6 days after erythema)Pruritus (can lead to lichenification)EyesEyelid swelling may lead to ectropion (eyelid eversion), blepharitis, epiphora (excessive tearing), ectropion (eyelid eversion)Palms/solesMay develop yellowish, diffuse keratodermaNailsDull, ridged, thickenedMay develop onycholysis and shed (onychomadesis)Lymph nodesGeneralized lymphadenopathy which may be reactive or suggestive of lymphomaHairTelogen effluvium (scaling of the scalp) leading to varying degrees of hair loss

Atypical Presentation {#Sec3}
=====================

Table 19.3Uncommon causes of erythrodermaStevens-Johnson syndromeToxic epidermal necrolysisToxic shock syndromeStasis dermatitis (venous eczema)Seborrheic dermatitisStaphylococcal scalded skin syndromeBlistering diseases including pemphigus and bullous pemphigoidSezary syndromeRare congenital ichthyotic conditions

Associated Systemic Symptoms {#Sec4}
============================

Systemic symptomsrelated to erythroderma itself or to the primary disease can be observed. Many of these features can lead to serious sequelae and are discussed further in the complications section. Patients often are unwell appearing and report chills, fever, fatigue, and malaise. Lymphadenopathy and (rarely) splenomegaly can be observed. Hepatomegaly is seen in 1/3 of cases and is most common in drug-induced erythroderma \[[@CR7], [@CR22]\]. Significant protein loss exceeding 9 g/m^2^ body surface per day as a consequence of skin exfoliation can lead to hypoalbuminemia, edema, and muscle wasting \[[@CR12]\]. As a result, patients may experience loss in temperature regulation and up to 50% of patients develop pretibial and pedal edema \[[@CR2], [@CR3]\].

When erythroderma occurs secondary to drug reaction, eosinophilia can be observed along with systemic symptoms characteristic ofDRESS (drug reaction and systemic symptoms; see Chap. 10.1007/978-3-319-75623-3_20) \[[@CR2]\].

Time Course of Disease {#Sec5}
======================

Erythrodermamay develop rapidly over hours to days or more gradually over weeks to month (see Table [19.4](#Tab4){ref-type="table"}) \[[@CR22]\]. Patients may initially present as medically stable or with life-threatening complications \[[@CR3]\].Table 19.4Typical course of disease according to etiology \[[@CR22]\]OnsetFeaturesDurationPrimary cutaneousSlower/indolentErythematous patches of increasing size with variable islands of sparingSubsequent scalingVariableDrug-inducedAbruptMorbilliform or urticarial followed by erythematous patches which increase in sizeComparatively quick resolutionSystemicGradualInitially characteristic of disease before patches form and coalesceVariableIdiopathicUnpredictable

The duration of erythroderma is highly variable and is determined by the underlying cause. Erythroderma as a result of primary skin disease is typically a gradual course with a median duration of 10 months but can go on to last years \[[@CR7]\].

The disease evolves more rapidly when it is a result of drug hypersensitivity reaction, lymphoma, or leukemia. In the setting of systemic disease, symptoms may persist from weeks to years -- dependent on the course of the underlying disorder. Conversely, in the case of drug-induced erythroderma, resolution of disease can occur in as little as 2--6 weeks after discontinuation of the offending agent \[[@CR3]\]. Patients with DRESS, however, may take longer to recover -- over weeks to months with possible relapse (*see* Chap. 10.1007/978-3-319-75623-3_20).

Common Mimics and Differential Diagnosis {#Sec6}
========================================

The diagnosis of erythroderma is difficult given it is usually a manifestation of an underlying diagnosis or exacerbation of primary disorder (Table [19.5](#Tab5){ref-type="table"}). Additionally, the characteristic physical findings of erythroderma generally obscure underlying disease features.Table 19.5Common mimics of erythroderma, often implicated as precipitating factorsAcanthosis nigricansAllergic contact dermatitisBullous pemphigoidContact dermatitisCutaneous T-cell lymphomaFamilial benign pemphigus (Hailey-Hailey disease)Graft-versus-host diseaseLichen planusMalignancyPediatric atopic dermatitisPemphigus foliaceusPityriasis rubra pilarisPlaque psoriasisReactive arthritisRapid vancomycin infusionSarcoidosisSeborrheic dermatitisStasis dermatitis

Key Physical Exam Findings and Diagnosis Features {#Sec7}
=================================================

As the list of causative factors of erythroderma continues to expand, it becomes more difficult to pinpoint the precipitating diagnosis \[[@CR22]\]. Because of this, a thorough history of presenting illness is of utmost importance in diagnosing erythroderma \[[@CR23]\]. Patients must be asked about all medications, preexisting medical conditions, allergies, and previous diagnoses of rash and skin disorders \[[@CR7], [@CR22]\].

Physical examination is crucial in attempts to detect an underlying etiology as well as to evaluate for systemic involvement and potential complications (i.e., organomegaly, lymphadenopathy, peripheral edema, infection, heart failure, and potential respiratory compromise) \[[@CR7], [@CR18], [@CR24]\].

Following a detailed history and physical, a skin biopsy, laboratory studies, imaging, and histology may useful adjuncts to derive a definitive diagnosis and exclude clinical mimics (see Fig. [19.6](#Fig6){ref-type="fig"}). These ancillary studies are often nonspecific, although with repeat testing the diagnosis may become apparent over time (Table [19.6](#Tab6){ref-type="table"}) \[[@CR11], [@CR15], [@CR16]\].Fig. 19.6Elderly patient with near erythroderma. Microscopy confirmed scabies infestation. (Used with permission from Rothe et al. \[[@CR3]\])Table 19.6Diagnostic features of underlying disordersSkin exam features \[[@CR3], [@CR18], [@CR26]\]Blisters and crusting: secondary infection, autoimmune blistering disorders (bullous pemphigoid, pemphigus foliaceusLarge scales: psoriasisFine scales: atopic dermatitis/dermatophyte infectionBurn-like scale: seborrheic dermatitisIslands of sparing/yellow tinge to the skin/hyperkeratosis of the palms and soles: pityriasis rubra pilaris (PRP)Laboratory testingLeukocytosis, increased ESR, anemia, hypoalbuminemia, and hyperglobulinemia are frequent findings in all causesEosinophilia in patients with DRESSIncreased IgE may be noted in atopic dermatitisConsider peripheral blood smears and bone marrow examination if leukemia is consideredSkin biopsyConsider if cause unknown although tend to be nonspecificRepeated biopsies may be necessarySkin scrapings may show hyphae or mitesImaging \[[@CR22]\]If cause is unknown, imaging may be performed as a survey for occult malignancyChest radiograph can identify infections, inflammatory disorders such as sarcoidosis with hilar lymphadenopathy, and congestive heart failureCultures/PCREvaluation for suprainfection, fungal infections, herpes simplex virus, and varicella zoster virusHistological \[[@CR27]--[@CR30]\]In all comers, hyperkeratosis, acanthosis, spongiosis, and perivascular inflammatory infiltrate are frequent findings in generalMay otherwise be nonspecificImmunofluorescence \[[@CR22], [@CR31]\]Of benefit in autoimmune blistering disease or connective tissue disease (i.e., immunoglobulins at the dermal-epidermal junction)

Management {#Sec8}
==========

Erythroderma is a dermatologic emergency which requires a dermatology consultation and hospital admission for severe cases to avoid potentially catastrophic complications. The principle management consists of discontinuation of all offending medications, maintaining skin moisture and integrity (through aggressive wound care), adequate hydration and nutrition, electrolyte repletion, and antibiotics forsecondary infection (Table [19.7](#Tab7){ref-type="table"}). Erythroderma as an isolated process will persist until the underlying condition is addressed, and the primary etiology may impact disease course and management options. Therefore, once the underlying diagnosis is established,targeted therapy should be administered promptly (Table [19.8](#Tab8){ref-type="table"}).Table 19.7Initial managementSystemic symptoms \[[@CR3]\]Replacement of fluid and electrolytesMonitoring hemodynamic statusMonitoring and regulation of body temperatureNutritional supportTreatment of skin inflammation and pruritusDiscontinuation of all offending/unnecessary medicationsDiuretics for refractory edemaSkin inflammation and pruritus \[[@CR3], [@CR22], [@CR32]\]Topical corticosteroids and oral antihistaminesOatmeal baths or warm wet compresses (no more than a quarter of the body at a time)Bland emollients or petrolatum for patient comfortInfectionsBlood culturesBroad-spectrum antibiotic coverage (to include MRSA)Antiviral medications where appropriateTable 19.8Targeted treatment modalitiesAtopic dermatitis \[[@CR22], [@CR33]--[@CR36]\]Avoiding allergensTopical and systemic steroidsIn refractory cases: cyclosporine, methotrexate, azathioprine, mycophenolate mofetil, and/or interferonPsoriasis \[[@CR37]--[@CR40], [@CR51]--[@CR53]\]Topical steroidsPhototherapyMethotrexateRetinoids (i.e., acitretin)CyclosporineIn refractory cases: tumor necrosis factor (TNF) inhibitors, interleukin (IL) inhibitors, phosphodiesterase type 4 \[PDE-4\] inhibitors (i.e., infliximab, adalimumab, etanercept, ustekinumab, secukinumab) \*this therapy can cause mycosis fungoides to progressMycosis fungoides \[[@CR41]--[@CR45]\]Topical corticosteroidsTopical chemotherapyTopical retinoidsMay consider phototherapy and radiotherapyIn refractory cases: interferon, oral retinoids, histone deacetylase inhibitors, monoclonal antibodies, photopheresis, and chemotherapyRarely stem cell transplantation consideredCutaneous T-cell lymphoma \[[@CR25]\]MethotrexatePotent topical steroidsChemotherapyUV lightSezary syndrome \[[@CR46]\]Extracorporeal photochemotherapySystemic retinoidsInterferonPityriasis rubra pilaris (PRP) \[[@CR22], [@CR47]\]Systemic retinoids as first lineTopical steroids as adjunct to palms, soles, face, skin folds, and extremitiesMay consider *methotrexate*, TNF-alpha inhibitors, *cyclosporine*, and azathioprineDrug induced \[[@CR2], [@CR7], [@CR35]\]Discontinue causative agentsShort-course oral steroids or pulse intravenous IV steroid therapyIdiopathic erythroderma \[[@CR1], [@CR5], [@CR9], [@CR11]\]Low to mid-potency topical corticosteroidsOral antihistaminesIn refractory cases: systemic corticosteroids

If a cause can be identified, then specific treatment should be initiated. Notably, systemic steroid should be avoided in psoriasis and staphylococcal scalded skin syndrome.

Complications {#Sec9}
=============

While the physiologic demands of erythroderma are tolerated by many patients, those at the extremes of age and patients with multiple comorbidities may suffer life-threatening consequences (see Table [19.9](#Tab9){ref-type="table"}). The shunting of blood through the skin due to peripheral vasodilation can result in high-output heart failure \[[@CR3]\]. These patients can present with tachycardia and pulmonary edema. Increased skin perfusion also results in temperature dysregulation and fluid and electrolyte imbalance. Exfoliation and protein loss result in edema and leave patient's susceptible to secondary infections \[[@CR12]\]. Acute respiratory distress syndrome (ARDS) is also a common complication.Table 19.9Physiologic derangementsProtein lossEdemaHypoalbuminemiaFluid lossTemperature dysregulationElectrolyte and metabolic disturbancesHigh output cardiac failureSepsis from superinfection

End-organ damage may develop such as hepatitis, myocarditis, and/or interstitial nephritis \[[@CR2]\].

Mortality rates range between 4 and 64% depending on the patient population \[[@CR7], [@CR22]\].

Bottom Line: Erythroderma Clinical Pearls {#FPar1}
-----------------------------------------

In the majority of cases, erythroderma results from an underlying condition and cannot itself be prevented \[[@CR22]\]. Individuals who develop erythroderma as a result of drug hypersensitivity should be instructed to avoid the offending agent in the future. Erythroderma as a result of underlying inflammatory skin condition will usually abate with treatment but may recur at any time. Idiopathic erythroderma is characterized by a more unpredictable course. Overall, prognosis of erythroderma is dependent on the underlying cause and is generally favorable if the underlying disease can be effectively treated \[[@CR48]--[@CR50]\].
